GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cellectar Biosciences
Cellectar is an oncology company developing a technology for delivering radioactive isotopes directly to cancer cells. Its stock price represents a venture bet on this platform. The chart reflects high volatility and dependence on news about clinical trials.
Share prices of companies in the market segment - General oncology therapy
Cellectar Biosciences is an oncology company developing drugs that deliver radioactive isotopes directly to cancer cells. We've categorized it as a "General Oncology" company. The chart below shows how the market values targeted radiotherapy platforms.
Broad Market Index - GURU.Markets
Cellectar Biosciences is an oncology company developing drugs that deliver radioactive isotopes directly to cancer cells. As an innovator, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Cellectar's performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
CLRB - Daily change in the company's share price Cellectar Biosciences
For Cellectar Biosciences, Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reactions to news about clinical trials of its radiopharmaceutical delivery platform.
Daily change in the price of a set of shares in a market segment - General oncology therapy
Cellectar Biosciences, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with CLRB's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Cellectar Biosciences is a biotech company developing radiopharmaceuticals for cancer treatment. Its shares move in sync with clinical trial news, and their high volatility is part of the overall market movement where science meets finance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cellectar Biosciences
Cellectar Biosciences' year-to-date performance is the story of its unique platform for delivering radioisotopes to tumors. Its 12-month market cap is entirely dependent on clinical trial data. The success of its phospholipid-drug approach could lead to a breakthrough in targeted radiotherapy for various types of cancer.
Annual dynamics of market capitalization of the market segment - General oncology therapy
Cellectar Biosciences, Inc. is a late-stage biotech company developing radiation therapies for cancer treatment. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the high risks involved.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cellectar Biosciences, which develops radiopharmaceuticals, is another biotech story where science and regulators rule. Its year-over-year performance, compared to the market, demonstrates the high expectations for its technology for targeted radiation delivery to cancer cells, completely decoupling its stock from macroeconomic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cellectar Biosciences
Cellectar is an oncology company developing radiotherapeutic drugs. Its monthly performance is driven by progress in its clinical trials. News of its radioisotope delivery platform's research results are the main driver of its valuation.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
Cellectar Biosciences develops radiopharmaceuticals that deliver radioactive isotopes directly to cancer cells, killing them with minimal damage to healthy tissue. The graph below shows the overall dynamics in the oncology sector, reflecting interest in innovative targeted radiation therapy methods.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks often live in a world of their own, where clinical trial news trumps overall market trends. The chart below shows the pulse of the broader market. Does Cellectar Biosciences move in sync with it, or do its R&D developments create a completely independent story?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cellectar Biosciences
Cellectar, an oncology company developing a unique technology for targeted delivery of radioisotopes directly to cancer cells (PLE), is extremely volatile. Its weekly stock price is a direct reaction to clinical trial data demonstrating the efficacy and safety of this approach.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
Cellectar operates in the volatile biopharmaceutical sector, where investor sentiment often influences all players. M&A news or general regulatory changes can lift or derail the entire segment. The chart will reveal whether CLRB is moving with the industry or whether its unique radioisotope delivery technology is forging its own story.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
As a biotech company, Cellectar Biosciences often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how CLRB shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
CLRB - Market capitalization of the company Cellectar Biosciences
The Cellectar Biosciences chart tells the story of "smart" radiation delivery to cancer cells. The company is developing a technology that delivers radioactive isotopes directly to tumors. Its market capitalization dynamics reflect investors' speculative bets on this cutting-edge, yet high-risk, approach to oncology.
CLRB - Share of the company's market capitalization Cellectar Biosciences within the market segment - General oncology therapy
Cellectar Biosciences develops radiopharmaceuticals that selectively deliver radiation to cancer cells. Its market share in the oncology sector is based on this targeted platform. The chart shows how the market values its ability to create "radioactive shuttle molecules" for the treatment of various tumors.
Market capitalization of the market segment - General oncology therapy
Cellectar Biosciences is developing a technology to deliver chemotherapy directly to cancer cells, minimizing damage to healthy tissue. The chart below shows the market capitalization of the oncology sector. This represents one of the "holy grails" of cancer treatment: high efficacy with low toxicity.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cellectar develops drugs that selectively deliver radioisotopes to cancer cells. Its market capitalization is driven by its radiopharmaceutical platform. The chart below shows the growing economic importance of this area of oncology treatment.
Book value capitalization of the company, segment and market as a whole
CLRB - Book value capitalization of the company Cellectar Biosciences
Cellectar Biosciences is based on a unique drug delivery technology. The company's book value reflects its patents for the Phospholipid Drug Conjugate™ (PDC) platform, which delivers radioisotopes precisely to cancer cells, and its R&D capital. The chart below shows the financial foundation on which this promising oncology technology is built.
CLRB - Share of the company's book capitalization Cellectar Biosciences within the market segment - General oncology therapy
Cellectar Biosciences, an oncology company, is focused on R&D. Its laboratories are its main tangible asset. The S_BCap_Seg graph shows its small share of physical infrastructure, which is typical for a biotech company.
Market segment balance sheet capitalization - General oncology therapy
Cellectar Biosciences develops radiopharmaceuticals for targeted cancer therapy. Its value lies in its unique technology for delivering radiation to tumors. The chart shows that its assets are almost entirely intangible, reflecting a focus on research rather than manufacturing.
Book value of all companies included in the broad market index - GURU.Markets
Cellectar's assets are based on "radioactive courier" technology. The company's book value reflects its rights to the PDC platform, which delivers radioisotopes precisely to cancer cells, and its capital for clinical trials. This provides the foundation for the development of a new class of targeted radiation therapy.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cellectar Biosciences
Cellectar Biosciences develops radiopharmaceuticals that deliver radiation directly to cancer cells. Its book value is low. Its market capitalization reflects its unique delivery platform and the potential of its drug candidates to treat difficult-to-treat cancers.
Market to book capitalization ratio in a market segment - General oncology therapy
Cellectar Biosciences develops radiopharmaceuticals that deliver radiation directly to cancer cells. This is cutting-edge technology. The chart shows the market premium for its innovative platform compared to its tangible assets.
Market to book capitalization ratio for the market as a whole
Cellectar Biosciences develops radiopharmaceuticals that deliver radiation directly to cancer cells. The company's value lies in its unique platform technology. The chart shows how the market is evaluating this innovative approach to cancer treatment.
Debts of the company, segment and market as a whole
CLRB - Company debts Cellectar Biosciences
Cellectar Biosciences, an oncology company, is using debt to finance its chemotherapy delivery platform. This chart shows the capital raised to conduct clinical trials of its drugs, which specifically deliver radioactive isotopes to cancer cells while minimizing harm to healthy tissue.
Market segment debts - General oncology therapy
Cellectar Biosciences is an oncology company developing technology for the targeted delivery of radioisotopes to cancer cells. This innovative approach requires significant and long-term investment. This chart shows how the company funds this cutting-edge R&D through equity capital.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cellectar Biosciences
Cellectar Biosciences develops radiopharmaceuticals for cancer treatment. This chart shows how the company finances its cutting-edge, yet capital-intensive, research. Raising debt in this field is a sign of high confidence in the technology, but also carries a huge risk if clinical trials don't meet expectations.
Market segment debt to market segment book capitalization - General oncology therapy
Cellectar Biosciences is an oncology company developing radiopharmaceuticals. This chart for the biotech sector illustrates how the industry as a whole raises capital to fund innovative and capital-intensive research. It provides context for assessing the company's financial strategy in this cutting-edge field.
Debt to book value of all companies in the market
Cellectar Biosciences develops radiopharmaceuticals for the precise delivery of radiation to cancer cells. This chart, showing the market's debt-to-book value ratio, is important for assessing the investment climate. The market's willingness to finance innovative approaches in oncology determines Cellectar's ability to advance its expensive research.
P/E of the company, segment and market as a whole
P/E - Cellectar Biosciences
Cellectar Biosciences develops radiopharmaceuticals that deliver radiation directly to cancer cells. This chart reflects its confidence in its payload delivery platform. Its value shows how much investors are willing to invest in this technology, which promises more effective and less toxic treatments for various cancer types.
P/E of the market segment - General oncology therapy
Cellectar Biosciences, Inc. is a biotech company. This chart shows the average P/E for the biotech sector. Comparing the company's P/E to this benchmark allows us to understand how highly the market values its radiopharmaceutical platform compared to the average prospects of other oncology developments.
P/E of the market as a whole
Cellectar Biosciences develops radiopharmaceuticals that deliver radiation directly to cancer cells. This chart shows the sentiment in the biotech sector. The company's valuation depends on the success of its delivery platform in clinical trials and whether it can carve out a niche in the growing field of radiopharmaceuticals.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cellectar Biosciences
Cellectar Biosciences develops radiopharmaceuticals for targeted radiation delivery to cancer cells. The chart below reflects investor expectations for this platform. Future revenue is entirely dependent on the success of clinical trials and the ability to demonstrate the benefits of this approach.
%20P%2FE%20Cellectar%20Biosciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cellectar-Biosciences&v=1772576806423 "Chart of the company's future (projected) P/E Cellectar Biosciences")
Future (projected) P/E of the market segment - General oncology therapy
Cellectar Biosciences develops radiopharmaceuticals that selectively deliver radiation to cancer cells. This chart shows how its future revenue expectations compare to the industry average, reflecting its potential to create a new class of targeted oncology therapies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772576806532 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
Cellectar Biosciences develops radiopharmaceuticals for targeted radiation delivery to cancer cells. This is an innovative approach in oncology. The company's valuation is not based on market forecasts, but rather on the success of its unique technological platform and clinical trial data.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772576806674 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cellectar Biosciences
Cellectar Biosciences is a late-stage oncology company developing drugs that selectively deliver radioisotopes to cancer cells. Its financial indicators reflect the costs of key clinical trials. This chart shows investments in developing a targeted radiation therapy platform that can be used in various cancer types.
Profit of companies in the market segment - General oncology therapy
Cellectar Biosciences is a late-stage oncology company developing drugs that deliver radioactive isotopes directly to cancer cells. This chart reflects the overall profitability of its sector. This technology could become a new platform for treating various types of cancer. Success in its clinical trials could dramatically change the overall profitability picture.
Overall market profit
Cellectar Biosciences develops radiopharmaceuticals that deliver radiation directly to cancer cells. The company's success depends on the results of clinical trials of this innovative technology. This graph shows common economic cycles as Cellectar works at the forefront of nuclear medicine, creating a new paradigm in cancer treatment.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cellectar Biosciences
Cellectar Biosciences develops radiopharmaceuticals that deliver radiation directly to cancer cells. This chart reflects analysts' future earnings expectations based on the potential of this targeted technology. It demonstrates market confidence in the company's ability to successfully complete clinical trials and develop a new class of oncology drugs.
%20profit%20of%20the%20company%20Cellectar%20Biosciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cellectar-Biosciences&v=1772576806875 "Graph of future (projected) profit of the company Cellectar Biosciences")
Future (predicted) profit of companies in the market segment - General oncology therapy
Cellectar Biosciences, Inc. develops radiopharmaceuticals that deliver isotopes directly to cancer cells. This chart shows profitability projections for the oncology sector. It reflects expectations for innovative radiation therapy methods that could be more precise and safer.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772576806882 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
Cellectar Biosciences is a clinical-stage oncology company. Their future depends entirely on successful trials and their ability to finance them. The market's overall profit forecast, reflected in the chart, influences investors' risk appetite. Economic optimism facilitates raising capital for such long-term projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772576806894 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cellectar Biosciences
Cellectar Biosciences develops radiopharmaceuticals for the precise delivery of radiation to cancer cells. Currently in the clinical stage, the company has no revenue. P/S will be important after the product launch to assess the potential of its payload delivery platform.
P/S market segment - General oncology therapy
Cellectar Biosciences develops radiopharmaceuticals that deliver radioactive isotopes directly to cancer cells, minimizing damage to healthy tissue. This chart shows how investors view their innovative payload delivery platform and its potential for treating various types of cancer.
P/S of the market as a whole
Cellectar Biosciences develops radiopharmaceuticals that deliver radiation directly to cancer cells. The company has no revenue, and its valuation is based on the potential of its platform. This chart, showing real revenue estimates, highlights the speculative nature of investing in Cellectar.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cellectar Biosciences
Cellectar Biosciences develops radiopharmaceuticals that deliver radiation directly to cancer cells. This chart reflects investor expectations for future revenue from this targeted technology, which can be used to treat a wide range of oncological diseases.
%20P%2FS%20Cellectar%20Biosciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cellectar-Biosciences&v=1772576806999 "The graph of the company's future (projected) P/S Cellectar Biosciences")
Future (projected) P/S of the market segment - General oncology therapy
Cellectar Biosciences, Inc. is a late-stage oncology company developing drugs that specifically deliver radioisotopes to cancer cells. This chart shows how the market views the future potential of its unique delivery platform. It compares it to other companies in the general oncology sector, reflecting confidence in its technology.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772576807005 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
Cellectar Biosciences develops radiopharmaceuticals that deliver radiation directly to cancer cells. This is a promising area of research in oncology. This chart shows overall revenue forecasts, and CLRB illustrates how new cancer treatments that combine chemistry and physics are shaping investor expectations.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772576807050 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cellectar Biosciences
Cellectar Biosciences is a late-stage oncology company developing targeted radiopharmaceuticals. Because its lead product has not yet received commercial approval, the company has no sales revenue. Its activities are financed through capital raising and potential partnerships.
Sales of companies in the market segment - General oncology therapy
Cellectar Biosciences is a biopharmaceutical company developing radiopharmaceuticals for cancer treatment. At this stage, its revenue, if any, may come from licensing agreements or grants. This chart allows investors to assess the external financial support for its innovative platform.
Overall market sales
Cellectar Biosciences develops radiopharmaceuticals for cancer treatment. Its technology delivers radiation directly to tumor cells. The company's success depends on clinical data. This overall economic activity chart is not relevant for assessing Cellectar, which operates at the forefront of oncology.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cellectar Biosciences
Cellectar Biosciences develops radiopharmaceuticals that deliver radiation directly to cancer cells. Its revenue forecast depends on the success of clinical trials. This chart reflects analysts' speculative expectations for its innovative targeted radiation therapy platform.
%20sales%20of%20the%20company%20Cellectar%20Biosciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cellectar-Biosciences&v=1772576807174 "Schedule of future (projected) sales of the company Cellectar Biosciences")
Future (projected) sales of companies in the market segment - General oncology therapy
Cellectar Biosciences develops radiopharmaceuticals that deliver isotopes directly to cancer cells. This chart displays projected revenues for the entire oncotherapy segment. It allows one to estimate the growth potential of the targeted radiotherapy market, which is key to the commercialization of Cellectar's innovative platform.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772576807194 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
Cellectar Biosciences is a biopharmaceutical company developing radiotherapeutic drugs for the treatment of cancer. Its success depends on the results of clinical trials. The overall economic situation, shown in this chart, influences the investment climate. Positive market expectations facilitate the raising of capital necessary for R&D.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772576807251 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cellectar Biosciences
Cellectar Biosciences is a clinical-stage oncology company developing drugs for targeted delivery of radioisotopes to cancer cells. This chart reflects the financial implications of this cutting-edge research. Future profitability depends entirely on the success of its clinical programs.
Market segment marginality - General oncology therapy
Cellectar Biosciences develops radiopharmaceuticals that specifically deliver isotopes to cancer cells. This graph shows the average profit margin in the oncology therapeutics sector. It helps assess the commercial potential of Cellectar's innovative delivery platform for creating more effective and safe cancer treatments.
Market marginality as a whole
Cellectar Biosciences, Inc. develops radiopharmaceuticals for the precise delivery of radiation to cancer cells. This overall profitability chart doesn't reflect the company's business, which operates at the intersection of nuclear medicine and oncology and strives to create more effective and safer treatments.
Employees in the company, segment and market as a whole
Number of employees in the company Cellectar Biosciences
Cellectar Biosciences is a late-stage oncology company developing radiopharmaceuticals. The growth of its team, visible in the graph, reflects preparations for the potential commercial launch of its lead candidate and the expansion of its clinical programs.
Share of the company's employees Cellectar Biosciences within the market segment - General oncology therapy
Cellectar Biosciences, Inc. is a late-stage biopharmaceutical company developing radiopharmaceuticals for cancer treatment. This chart illustrates its innovative approach to oncology. It reflects the number of radiochemists and oncologists working on creating "smart" molecules that deliver radiation directly to cancer cells that Cellectar brings together.
Number of employees in the market segment - General oncology therapy
Cellectar Biosciences, Inc. is an oncology company developing drugs for the targeted delivery of radioisotopes to cancer cells. This chart shows employment in the oncology therapeutics sector. Growth in this cutting-edge field reflects the development of radiopharmaceuticals as a promising approach to cancer treatment.
Number of employees in the market as a whole
Cellectar Biosciences, Inc. is a biopharmaceutical company developing targeted radiopharmaceuticals for cancer treatment. This innovative approach combines chemotherapy and radiation therapy. This chart shows overall occupancy, and these companies are demonstrating progress in creating more precise and effective treatments.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cellectar Biosciences (CLRB)
Cellectar Biosciences is an oncology company with a unique drug delivery platform. This chart shows how the market values this intellectual capital. The high cost per employee is a premium for technology that can make existing drugs more effective and safer.
%20of%20the%20company%20Cellectar%20Biosciences%20(CLRB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cellectar-Biosciences-CLRB&v=1772576807665 "Chart of market capitalization per employee (in thousands of dollars) of the company Cellectar Biosciences (CLRB)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
Cellectar Biosciences develops radiopharmaceuticals for targeted radiation delivery to cancer cells. Its market capitalization per employee reflects the value of its unique platform. This high figure suggests investors see significant potential in its ability to precisely destroy tumors while minimizing damage to healthy tissue.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772576807693 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Cellectar Biosciences develops radiopharmaceuticals that deliver radiation directly to cancer cells. This is an innovative approach in oncology. This chart shows how investors view the potential of this technology and the team's ability to create a new class of anti-cancer drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772576807701 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cellectar Biosciences (CLRB)
Cellectar Biosciences is an oncology R&D company developing a platform for precisely delivering radioactive isotopes and drugs to cancer cells (PDC). This negative graph shows how much capital is being burned for each scientist trying to bring this smart drug delivery technology to the clinic.
%20Chart%20Cellectar%20Biosciences%20(CLRB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cellectar-Biosciences-CLRB&v=1772576807711 "Company Profit Per Employee (in thousands of dollars) Chart Cellectar Biosciences (CLRB)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
Cellectar Biosciences develops radiopharmaceuticals that deliver isotopes directly to cancer cells. This graph highlights the potential value of their delivery platform. It illustrates how an innovative targeting method can create highly effective and, therefore, commercially successful drugs, generating significant profit potential for the company.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772576807737 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Cellectar Biosciences develops radiopharmaceuticals (PDC technology) that deliver radiation directly to cancer cells. This is high-tech R&D. This chart shows R&D costs per employee. It shows how much the company is investing in developing its unique isotope delivery platform.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772576807745 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cellectar Biosciences (CLRB)
Cellectar Biosciences is a late-stage oncology company. This graph doesn't reflect commercial viability until its products are commercialized. It represents potential. Successful approval and launch of radiopharmaceuticals will lead to a sharp increase in this metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cellectar-Biosciences-CLRB&v=1772576807771 "Sales chart per company employee Cellectar Biosciences (CLRB)")
Sales per employee in the market segment - General oncology therapy
Cellectar Biosciences (CLRB) is an oncology company developing a platform for delivering radioactive isotopes (radiopharmaceuticals) directly to cancer cells. This chart shows the average revenue per employee in the pharmaceutical segment. For Cellectar, which is in the R&D stage, comparing it to this benchmark (zero) underscores their focus on science.
Sales per employee for the market as a whole
Cellectar Biosciences (CLRB) is a clinical-stage biotech company (oncology), developing a technology for "radioactive delivery" to tumors. There is no revenue. This metric is irrelevant. The entire value lies in the potential of their scientific platform.
Short shares by company, segment and market as a whole
Shares shorted by company Cellectar Biosciences (CLRB)
Cellectar Biosciences is a biotech company developing a platform for delivering radioactive isotopes to cancer cells (radiopharmaceuticals). This chart reflects skepticism. Bears are betting that their technology will prove too toxic or insufficiently effective, or that the company will be unable to scale up the complex manufacturing of these drugs.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cellectar-Biosciences-CLRB&v=1772576807860 "Short Shares Chart for the Company Cellectar Biosciences (CLRB)")
Shares shorted by market segment - General oncology therapy
Cellectar (CLRB) is a biotech developing "radioactive couriers" (PDCs) that deliver radiation precisely to tumors. This chart highlights the pessimism in the sector. The growing short position in the industry is a bet that this complex technology will not take off. Investors are wary of the risks associated with "radiopharmaceuticals" (production, safety) and doubt the effectiveness of this approach.
Shares shorted by the overall market
Cellectar Biosciences is developing a technology for targeted radiation delivery to cancer cells. This is a high-risk biotech. This chart illustrates the overall market pessimism. When investors are fearful, they are unwilling to take scientific risks. Any delay in trials amid panic is perceived as a failure.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cellectar Biosciences (CLRB)
This chart for Cellectar is a barometer of faith in "radioactive packages" technology. The company is developing the CLR 131 platform, which delivers radioisotopes precisely to cancer cells. "Overbought" levels (above 70) are driven by positive trial data across various cancer types. The complexity of the technology and the high risk of failure in late-stage trials keep investors on edge, often leading to "oversold" levels.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cellectar-Biosciences-CLRB&v=1772576807952 "RSI 14 indicator chart for the company's stock Cellectar Biosciences (CLRB)")
RSI 14 Market Segment - General oncology therapy
Cellectar is "radiation" against cancer. Their platform (PDC - Phospholipid Drug Conjugate) delivers radioactive isotopes directly to cancer cells. The "General Oncology Therapy" sector (biotech/radiopharmaceuticals) thrives on hype. RSI_14_Seg shows the "temperature" of the *entire* industry. It helps us understand: is CLRB's growth a niche or a result of the *general* hype?
RSI 14 for the overall market
Cellectar (CLRB) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CLRB (Cellectar Biosciences)
Cellectar (CLRB) develops "radiopharmaceutical conjugates" (PDCs) that deliver radiation precisely to cancer cells. This chart shows the average price target. It reflects analysts' confidence in this "radioactive Trojan horse" platform and its clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CLRB-Cellectar-Biosciences&v=1772576808106 "A chart showing analyst consensus forecasts for the expected stock price. CLRB (Cellectar Biosciences)")
The difference between the consensus estimate and the actual stock price CLRB (Cellectar Biosciences)
Cellectar is an oncology company developing a radioactive isotope delivery system (PDC) that binds to and destroys cancer cells. This chart clearly demonstrates the gap between the price and analysts' forecasts, reflecting their confidence in this targeted radiotherapy technology and its R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CLRB-Cellectar-Biosciences&v=1772576808164 "A chart showing the difference between the consensus forecast and the actual stock price. CLRB (Cellectar Biosciences)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
Cellectar is a "mailman" for radiation. The company is developing a platform (PDC) that delivers radioactive isotopes precisely to cancer cells, sparing healthy tissue. This chart reflects the general expectations of analysts across the oncology sector. It shows whether experts believe in the future of targeted "radio-pharma."
Analysts' consensus forecast for the overall market share price
Cellectar Biosciences is a biotechnology company developing a platform (PLE) for the targeted delivery of radioactive isotopes directly to cancer cells. This chart shows the overall risk appetite in the market. For Cellectar, which operates in a cutting-edge but complex field, overall market optimism (an upward trend in the chart) is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cellectar Biosciences
Cellectar is a radioactive Trojan horse. Their gimmick is an R&D platform (CLR) that delivers radioactive isotopes (chemicals) only to cancer cells, tricking them and sparing healthy tissue. This chart is a pure indicator of faith in their R&D. It doesn't reflect revenue, but rather a speculative valuation of their delivery platform and their progress in clinical trials.
AKIMA Market Segment Index - General oncology therapy
Cellectar Biosciences (CLRB) develops radiotherapeutic drugs based on its Phospholipid Drug Conjugate (PDC) platform. This technology delivers radiation precisely to cancer cells while sparing healthy cells. The chart shows the average index for the segment, helping investors assess how this targeted radiotherapy delivery compares to the oncology industry average.
The AKIM Index for the overall market
Cellectar Biosciences is a radiopharmaceutical company developing phospholipid conjugates (CLR 131) for targeted radiation delivery to cancer cells. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this late-stage research story compares to overall economic trends in oncology.
